Hepatitis C drugs: The end of the pegylated interferon era and the emergence of all-oral, interferon-free antiviral regimens: a concise review

Canadian Journal of Gastroenterology and Hepatology

Volumn 28, Issue 8, 2014, Pages 445-451

  Yau, Alan Hoi Lun ^a   Yoshida, Eric M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

All oral; Hepatitis C; Interferon free; Simeprevir; Sofosbuvir

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON; RIBAVIRIN; INTERFERON;

ANTIVIRAL THERAPY; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; CROSS RESISTANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; QUALITY OF LIFE; REVIEW; ANTIVIRAL RESISTANCE; DRUG APPROVAL; DRUG COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; DRUG APPROVAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; RIBAVIRIN;

EID: 84907437241     PISSN: 22912789     EISSN: 22912797     Source Type: Journal    
DOI: 10.1155/2014/549624     Document Type: Review

References (64)

1. World Health Organization (WHO). Viral Hepatitis - Resolutions from the 63rd World Health Assembly, 2010.
2. Remis R. Modeling the incidence and prevalence of hepatitis C infection and its sequelae in Canada, 2007 final report. Public Health Agency of Canada. 2007.
3. Myers RP, Liu MF, Shaheen AAM. The burden of hepatitis C virus infection is growing: A Canadian population-based study of hospitalizations from 1994 to 2004. Can J Gastroenterol 2008;22:381-7.
4. Dungum M, O'Shea R. Hepatitis C virus: Here comes all-oral treatment. Cleve Clin J Med 2014;81:159-72.
5. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001;358:958-65.
6. Fried MW, Shiffman ML, Reddy R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
7. Hézode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicenter cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013;59:434-41.
8. Ward RP, Kugelmas M. Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C. Am Fam Physician 2005;72:655-62.
9. Bruchfeld A, Lindahl K, Stahle L, et al. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003;18:1573-80.
10. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: The best interferon-free combinations. Liver Int 2014;34(S1):69-78.
11. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomized, multicenter phase 2 trial. Lancet 2010;376:705-16.
12. Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
13. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
14. Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013;58:583-92.
15. Stedman CA. Current prospects for interferon-free treatment of hepatitis C in 2012. J Gastroenterol Hepatol 2013;28:38-45.
16. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17.
17. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28.
18. González-Moreno J, Payeras-Cifre A. Hepatitis C virus infection: Looking for interferon free regimens. Scientific World Journal 2013;2013(825375):1-11.
19. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naïve patients: Results from QUEST-1, a phase III trial. J Hepatol 2013;58:S567-577. Abst 1425.
20. Manns M, Marcellin P, Poordad FPF, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naïve patients: Results from QUEST-2, a phase III trial. J Hepatol 2013;58(S567-S577): Abst 1413.
21. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study. Hepatology 2013;58:1918-29.
22. Lawitz E, Zeuzem S, Gane E, et al. Simeprevir (TMC435) with pegylated interferon-α-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: Efficacy and safety in patient subpopulations in the PROMISE phase III trial. 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington DC, November 1 to 5, 2013.
23. Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: A phase IIb trial. Gastroenterology 2014;146:430-41.
24. Bae A, Sun SC, Qi X, et al. Susceptibility of treatment-naïve hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob Agents Chemother 2010;54:5288-97.
25. Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naïve patients with genotypes 1, 2, and 3 hepatitis C infection: A randomized, double-blind, phase 2 trial. Lancet Infect Dis 2013;13:401-8.
26. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naïve patients with hepatitis C genotype-1 infection (ATOMIC): An open-label, randomized, multicentre phase 2 trial. Lancet 2013;381:2100-7.
27. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87.
28. Lalezari J, Lawitz E, Rodriguez-Torres M, et al. Once daily PSI-7977 plus PegIFN/RBV in a phase 2b trial: Rapid virologic suppression in treatment-naive patients with HCV GT2/GT3. J Hepatol 2011;54(S25-S44):Abst 61.
29. Lawitz E, Poordad F, Brainard DM, et al. Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment-experienced patients with and without compensated cirrhosis: Results from the LONESTAR-2 study. 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington DC, November 1 to 5, 2013.
30. Younossi ZM, Stepanova M, Henry L, et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol 2014;60:741-7.
31. Younossi ZM, Stepanova M, Henry L, et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2013;S1542-3565(13)01838-7.
32. Younossi ZM, Singer ME, Mir HM, et al. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol 2014;60:530-7.
33. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): A randomized, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010;376:1467-75.
34. Lok AS, Gardiner AF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012;366:216-24.
35. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-77.
36. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: The VALENCE trial. 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington DC, November 1 to 5, 2013.
37. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368:34-44.
38. Lalezari JP, Nelson DR, Hyland RH, et al. Once-daily sofosbuvir plus ribavirin given for 12 or 24 weeks in treatment-naive patients with HCV infection: The QUANTUM study. J Hepatol 2013;58:S229-407.
39. Jacobson IM, Ghalib RH, Rodriguez-Torres M, et al. SVR results of a once-daily regimen of simeprevir (TMV435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study. 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington DC, November 1 to 5, 2013. Abst LB-3.
40. Sulkowski M, Jacobson IM, Ghalib R, et al. Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 prior null responders with metavir F0-2: COSMOS study subgroup analysis. J Hepatol 2014;60:S4. A7 (Abst).
41. Lawitz E, Ghalib R, Rodriguez-Torres M, et al. Simeprevir plus sofosbuvir with/without ribavirin in HCV genotype 1 prior null-responder/treatment-naïve patients (COSMOS study). Primary endpoint (SVR12) results in patients with metavir F3-4 (Cohort 2). J Hepatol 2014;60(1):S524:A165 (Abst).
42. Sharma P, Lok AS. Interferon-free treatment regimens for hepatitis C: Are we there yet? Gastroenterology 2011;141:1963-7.
43. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-88.
44. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomized, phase 2 trial. Lancet 2014;383:515-23.
45. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-21.
46. Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenteroloy 2014;146:736-43.
47. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-98.
48. Afdhal N, Reddy R, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-93.
49. Gane EJ, Pockros P, Zeuzem S, et al. Interferon-free treatment with a combination of mericitabine and danoprevir with or without ribavirin in treatment-naïve HCV genotype 1-infected patients. J Hepatol 2012;56:S555-6.
50. Feld JJ, Jacobson IM, Jensen DM, et al. Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine (MCB) and ribavirin (R) +/- peginterferon alfa-2a (40KD) (P) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study. Hepatology 2012;56(S4):231A-232A.
51. Lawitz E, Hezode C, Varunok P, et al. Interferon- and ribavirin-free regimen of ABT-450/r + ABT-267 in HCV genotype 1b-infected treatment-naïve patients and prior null responders (Abstr 75). 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC, November 1 to 5, 2013. (Abst)
52. Lawitz E, Sullivan G, Rodriguez-Torres M, et al. A 12-week trial of interferon-free regimens containing ABT-450/r and ABT-267 +/- ribavirin (RBV) in treatment-naïve patients with HCV genotypes 1-3. Hepatol Int 2013;7(S1):S358-9.
53. Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014;370:222-32.
54. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370:1983-92.
55. Lawitz E, Poordad F, Kowdley KV, et al. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. J Hepatol 2013;59:18-23.
56. Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013;368:45-53.
57. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1604-14.
58. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973-82.
59. Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012;55:742-8.
60. Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013;58:655-62.
61. Lok AS, Gardiner DF, Hezode C, et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol 2014;60:490-9.
62. Everson GT, Sims KD, Rodriguez-Torres M, et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naïve patients with HCV genotype 1 infection. Gastroenterology 2014;146:420-9.
63. Wyles DL, Rodriguez-Torres M, Lawitz E, et al. All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection. Hepatology 2014 (Epub ahead of print).
64. Lawitz E, Vierling J, Murillo A, et al. High efficacy and safety of the all-oral combination regimen, MK-5172/MK-8742 +/- RBV for 12 weeks in HCV genotype 1 infected patients: The C-WORTHY study. 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC, November 1 to 5, 2013.